Company / Total Assets
Apellis Pharmaceuticals, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$1.1B
FY2025
5-year range
$760.2M / $1.1B
FY2021-FY2025
Trend
+21.5%
vs FY2024
Sector context
#78 of 214
Health Care
What the data says
At $1.1B, Apellis Pharmaceuticals, Inc.'s total assets ranks #78 of 214 in the Health Care sector. Total Assets has increased for 3 consecutive years, from $760M in FY2022 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +2.3%.
Improved from $789M to $1.1B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Sector benchmark
#78 of 214 in Health CareTop 36% of 214This company $1.1B Sector average $7.5B
▼
-85.6% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +2.3%, indicating consistent growth.
- In FY2025, total assets increased 21.5% year-over-year.
- Ranks #78 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +21.5% |
| FY2024 | $885.1M | +12.2% |
| FY2023 | $788.7M | +3.8% |
| FY2022 | $760.2M | -13.8% |
| FY2021 | $881.8M | -8.2% |
| FY2020 | $960.6M | +146.8% |
| FY2019 | $389.2M | +91.2% |
| FY2018 | $203.5M | +11.8% |
| FY2017 | $182.1M | +563.9% |
| FY2016 | $27.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026